110 completed, 68 unknown, 35 recruiting, 23 terminated. 267 Phase 3, 34 Phase 2.
Follow Rectal Neoplasms: new trials by email Literature Review of Rectal Neoplasms trials Research Report on Rectal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer | Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 210 | 2026-10-25 | 2026-10-28 |
| A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer Dostarlimab - Neoplasms, Rectal | Phase 3 | Not yet recruiting | GlaxoSmithKline | 90 | 2026-09-17 | 2026-08-03 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer Short-course radiotherapy, Long-course radiotherapy, Capecitabine - Rectal Cancer, Total Neoadjuvant Therapy | Phase 3 | Recruiting | Tao Zhang | 444 | 2026-05-15 | 2026-05-13 |
| Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water, 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water., Microwave (thermal) tumor ablation - Colorectal Cancer (CRC), Colon Cancer Liver Metastases | Phase 2 / Phase 3 | Not yet recruiting | Immunophotonics, Inc. | 717 | 2026-05-01 | 2026-01-07 |
| Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer Pucotenlimab combine with CAPOX, CAPOX - Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | Recruiting | Sun Yat-sen University | 556 | 2026-04-20 | 2026-04-30 |
| Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. intestinal fluid infusion, potable water - Low Anterior Resection Syndrome, Rectal Cancer | Phase 2 / Phase 3 | Recruiting | Pei-Rong Ding | 160 | 2026-04-10 | 2026-04-17 |
| Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab - Anal Squamous Cell Carcinoma, Limited-stage | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 350 | 2026-03-17 | 2026-07-09 |
| Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria Experimental Group, Control group - Rectal Cancer | Phase 2 / Phase 3 | Recruiting | The First Hospital of Jilin University | 212 | 2026-02-23 | 2026-04-01 |
| Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance Intensified follow-up program - LARS - Low Anterior Resection Syndrome, Rectal Cancer Surgery | Phase 3 | Recruiting | University Hospital, Basel, Switzerland | 140 | 2025-12-01 | 2026-05-06 |
| ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer Adjuvant chemotherapy - Rectal Cancer | Phase 3 | Recruiting | Erasmus Medical Center | 103 | 2025-10-14 | 2026-10-02 |
| Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer serplulimabăbevacizumab, neoadjuvant chemoradiation therapy - Rectal Cancer | Phase 2 / Phase 3 | Not yet recruiting | Changhai Hospital | 180 | 2025-10-01 | 2025-08-21 |
| Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer Sildenafil, Placebo - Rectal Cancer | Phase 3 | Recruiting | University Hospital, Rouen | 188 | 2025-09-25 | 2026-05-12 |
| Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer Hyperthermia - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | Shih-Kai Hung | 126 | 2025-09-23 | 2026-01-28 |
| Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study Long-course chemoradiotherapy, Tislelizumab combined with the CAPOX regimen, CAPOX regimen - Rectal Cancer | Phase 3 | Recruiting | Fudan University | 196 | 2025-08-12 | 2026-09-21 |
| Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial TAS-102, Capecitabine - Rectal Cancer, Rectal Cancer Patients | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 210 | 2025-07-30 | 2026-10-15 |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 477 | 2025-07-16 | 2026-11-12 |
| Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal Cancer radiotherapy, Toripalimab, Surufatinib 250mg/d qd once daily - Rectal Cancer | Phase 2 / Phase 3 | Recruiting | The First Hospital of Jilin University | 32 | 2025-05-16 | 2026-11-13 |
| Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor, Conventional Radiotherapy plus Chemotherapy - Rectal Cancer, Neoadjuvant Therapies | Phase 2 / Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 430 | 2025-05-06 | 2026-09-28 |
| Bovine Reinforcement in Stomach, Colorectal and Lung Operation Bioabsorbable Staple Line Reinforcemen - Rectal Cancer Stage III, Lung Cancer Stage III | Phase 3 | Recruiting | Shanghai Cingularbio Co. Ltd | 172 | 2025-05-01 | 2025-05-15 |
Showing 20 of 267. Sign in to see all of them.
Colorectal Neoplasms (103) · Colonic Neoplasms (96) · Anus Neoplasms (25) · Neoplasm Metastasis (15) · Neoplasms (12) · Breast Neoplasms (8) · Uterine Cervical Neoplasms (7) · Anal Canal Carcinoma (6) · Prostatic Neoplasms (6) · Anastomotic Leak (5) · Condylomata Acuminata (5) · Breast Neoplasms, Male (4) · Carcinoma, Non-Small-Cell Lung (4) · Low Anterior Resection Syndrome (4)
Neoplasms by Site (267) · Digestive System Diseases (266) · Gastrointestinal Diseases (266) · Intestinal Diseases (266) · Rectal Diseases (266) · Digestive System Neoplasms (265) · Intestinal Neoplasms (265) · Gastrointestinal Neoplasms (264) · Neoplasms (255) · Colorectal Neoplasms (164) · Colonic Diseases (125) · Pathological Conditions, Signs and Symptoms (49) · Pathologic Processes (39) · Anus Diseases (24)
Fluorouracil (73) · Leucovorin (60) · Oxaliplatin (56) · Capecitabine (51) · Irinotecan (32) · Radiotherapy (27) · Bevacizumab (23) · Chemoradiotherapy (15) · Neoadjuvant Therapy (14) · Cetuximab (13) · Folfox protocol (13) · Chemotherapy, Adjuvant (10) · Drug Therapy (9) · Mitomycin (9) · Surgical Procedures, Operative (9)
Alliance for Clinical Trials in Oncology (14) · National Cancer Institute (NCI) (9) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Medical Research Council (7) · Sun Yat-sen University (6) · Blokhin's Russian Cancer Research Center (5) · Federation Francophone de Cancerologie Digestive (5) · GERCOR - Multidisciplinary Oncology Cooperative Group (5) · UNICANCER (5) · Amgen (4) · Fudan University (4) · Sixth Affiliated Hospital, Sun Yat-sen University (4) · West China Hospital (4) · Centre Hospitalier Universitaire, Amiens (3) · Memorial Sloan Kettering Cancer Center (3)
United States (71) · China (50) · France (44) · United Kingdom (30) · Canada (27) · Italy (23) · Germany (22) · Netherlands (22) · Belgium (21) · Australia (14) · Denmark (12) · South Korea (12) · Sweden (12) · Poland (11) · Spain (11)
Aimery de Gramont, MD (4) · Zaman Z Mamedli, PhD (4) · Jaffer A. Ajani, MD (3) · Matthew T. Seymour, MA, MD, FRCP (3) · Norman Wolmark, MD (3) · Timothy Maughan, MD (3) · Al B. Benson, MD, FACP (2) · Al Benson (2) · Alan Venook, MD (2) · Alfredo Falcone, MD (2) · Axel Grothey, MD (2) · Charles L. Loprinzi, MD (2) · Claus-Henning Koehne, MD (2)
PMID 37310167, PMID 20797891, PMID 23008301, PMID 27432930, PMID 29234923, PMID 30466310, PMID 40215447, PMID 41379261, PMID 10789750, PMID 10944647, PMID 11913730, PMID 12047964, PMID 12204666, PMID 12621132, PMID 12782596, PMID 14665611, PMID 15470715, PMID 15496622, PMID 15677624, PMID 15894098, PMID 15912493, PMID 15939923, PMID 15997446, PMID 16009958, PMID 16098249, PMID 16265352, PMID 16356309, PMID 16479065, PMID 16505413, PMID 16849748, PMID 16877719, PMID 16877722, PMID 16943394, PMID 16943400, PMID 16971718, PMID 17008704, PMID 17553204, PMID 17630037, PMID 17634484, PMID 17652651, PMID 17687151, PMID 17906203, PMID 18003960, PMID 18065406, PMID 18083404, PMID 18191265, PMID 18316791, PMID 18358928, PMID 18378608, PMID 18430910
U10CA021115 (4), U10CA031946 (4), U10CA032102 (3), 2018 (2), U01CA121947 (2), U10CA180820 (2), 2009 (1), 2015 (1), 2016 (1), 2023 (1), 2025 (1), K23CA115908 (1), N01CN95015 (1), P01CA041108 (1), P30CA023074 (1)